|
Ranbaxy Laboratories (Citi) Base Biz Improving; FDA Issues Commentary Positive |
|
Risk Reward Remains Favorable;Resolution to FDA/DoJ Issues in Sight?;Core Biz Margin Improving;Strong FTF/PIV Pipeline | Date | Rating | Target Price | Recommendation Price | Broker house | | 24 Jun 2011 | buy | 700 | 511 | Citi Report | |
|
ranbaxy (Emkay) Base business improves, Maintain Hold |
Revenue growth led by improvement in base business; Future growth will be a combination of successful monetization of key products and pick-up in the base business
| Date |
Rating |
Target Price |
Recommendation Price |
Broker house |
| 11 May 2011 |
hold |
412 |
478 |
Emkay Report |
Yahoo Link+NSE Link+Reuters Link+Reuters India Link+Google Link+DSR Search
Reports.DesiStockResearch.com |
|
ranbaxy (CreditSuisse) Base margins improved, but still long way to achieve mid-teen margins |
| Date |
Rating |
Target Price |
Recommendation Price |
Broker house |
| 11 May 2011 |
underperform |
450 |
441 |
CreditSuisse Report |
Yahoo Link+NSE Link+Reuters Link+Reuters India Link+Google Link+DSR Search
Reports.DesiStockResearch.com |
|
ranbaxy laboratories (GoldmanSachs) expectations: Donepezil discount steeper; margins improve |
| Date |
Rating |
Target Price |
Recommendation Price |
Broker house |
| 11 May 2011 |
neutral |
481 (from 495) |
449 |
GoldmanSachs Report |
Yahoo Link+NSE Link+Reuters Link+Reuters India Link+Google Link+DSR Search
Reports.DesiStockResearch.com |
|
ranbaxy laboratories (Angel) Better-than-expected 1QCY2011 results |
|
ranbaxy (Citi) Strong Numbers, Aricept Led |
Beats estimates; Steady revenue growth, excluding exclusivities; Margins stable; still room for improvement;
| Date |
Rating |
Target Price |
Recommendation Price |
Broker house |
| 11 May 2011 |
buy |
700 |
449 |
Citi Report |
Yahoo Link+NSE Link+Reuters Link+Reuters India Link+Google Link+DSR Search
Reports.DesiStockResearch.com |
|
ranbaxy laboratories (GoldmanSachs) expectations: Donepezil discount steeper; margins improve |
| Date |
Rating |
Target Price |
Recommendation Price |
Broker house |
| 11 May 2011 |
neutral |
481 (from 495) |
449 |
GoldmanSachs Report |
Yahoo Link+NSE Link+Reuters Link+Reuters India Link+Google Link+DSR Search
Reports.DesiStockResearch.com |
|
ranbaxy (DeutscheBank) US press reports potential USD 1bn US FDA settlement |
Potential USD 1bn settlement with US FDA.. will further erode value for Ranbaxy
| Date |
Rating |
Target Price |
Recommendation Price |
Broker house |
| 6 May 2011 |
sell |
190 |
453 |
DeutscheBank Report |
Yahoo Link+NSE Link+Reuters Link+Reuters India Link+Google Link+DSR Search
Reports.DesiStockResearch.com |
|
ranbaxy laboratories (GoldmanSachs) Potential US$1bn to settle FDA charges relating to Lipitor |
| Date |
Rating |
Target Price |
Recommendation Price |
Broker house |
| 5 May 2011 |
neutral |
495 |
453 |
GoldmanSachs Report |
Yahoo Link+NSE Link+Reuters Link+Reuters India Link+Google Link+DSR Search
Reports.DesiStockResearch.com |
|
ranbaxy (Citi) updated to reflect the full year result |
| Date |
Rating |
Target Price |
Recommendation Price |
Broker house |
| 1 May 2011 |
buy |
700 |
456 |
Citi Report |
Yahoo Link+NSE Link+Reuters Link+Reuters India Link+Google Link+DSR Search
Reports.DesiStockResearch.com |
